Core Insights - UroGen Pharma Ltd. is set to present at the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026, with a specific presentation scheduled for March 3, 2026, at 1:50 PM ET [1][2] Company Overview - UroGen Pharma is a biotech company focused on developing and commercializing innovative treatments for urothelial and specialty cancers, emphasizing the need for better patient options [3] - The company has developed RTGel®, a proprietary sustained-release hydrogel technology aimed at enhancing the therapeutic profiles of existing drugs, allowing for longer exposure of urinary tract tissue to medications [3] - UroGen's first product is approved for treating low-grade upper tract urothelial cancer, while its second product is the first FDA-approved medication for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, both designed for non-surgical tumor ablation [3]